# Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis

**Authors:** Md. Ahad Ali, Humaira Sheikh, Md. Selim Reza, Tripti Rani Paul, Tasfia Noor, Neeraj Kumar, Mashooq Ahmad Bhat, Md. Nurul Haque Mollah

PMC · DOI: 10.1371/journal.pone.0337970 · 2026-03-11

## TL;DR

This study identifies natural compounds in black cumin that may help treat SARS-CoV-2 infections by binding to key viral and host proteins.

## Contribution

The study proposes new phytocompounds from black cumin as potential drug candidates against SARS-CoV-2 using bioinformatics analysis.

## Key findings

- Five top phytocompounds from black cumin showed high binding affinity to SARS-CoV-2 and host proteins.
- Three compound-receptor complexes demonstrated stable binding through dynamic simulations and MM-GBSA studies.
- ADMET and DFT analyses confirmed the drug-likeness of the identified phytocompounds.

## Abstract

SARS-CoV-2 was identified at the end of 2019 as the key cause of COVID-19, a global pandemic. As remedies, different vaccines as well as synthetic drugs have been recommended. However, the availability of natural drugs against SARS-CoV-2 infection is limited, although natural drugs are considered as less toxic than synthetic drugs, and vaccine efficacy is gradually weakened due to unstable RNA sequence patterns of SARS-CoV-2. Black-cumin is a well-known medicinal plant, but it was not rigorously investigated against SARS-CoV-2 infections. This study attempted to investigate this issue, rigorously. In order to explore effective bioactive phytocompounds from black-cumin (BC) through bioinformatics analysis, we selected top-ranked 11 drug target proteins/receptors of which five receptors were SARS-CoV-2 proteins/proteases (S, N, RdRp, 3CLpro, PLpro) and the other six receptors were host proteins (ACE2, MAPK8, TMPRSS2, IL6, TNF, and NFKBIA) associated with the infection by the systematic literature review. We computed binding affinity scores (BAS) for each phytochemical of BC with each of those 11 receptors. Top-ranked five phytocompounds (Silibinin, Taraxerol, Beta amyrin, Cycloartenol, and Alpha-sitosterol) were selected based on their highest average BAS across our proposed receptor, these phytocompounds also showed better binding capabilities against the other independent receptors. Then we selected top-ranked three complexes (ACE2 vs. silibinin, Spike vs. beta amyrin, and MAPK8 vs. Taraxerol) to investigate their binding stability using dynamic simulation (i.e., RMSD, RMSF, DCCM, PCA, and FEL) and MM-GBSA studies and found their stable performance. The ADMET, Bioactivity, and DFT analysis results supported the drug-likeness properties of the proposed phytocompounds. Therefore, the findings of this article might be useful resources for taking an alternative treatment plan against SARS-CoV-2 infections.

## Linked entities

- **Proteins:** S (Star), N (Notch), RdRP (RNA-directed RNA polymerase), ACE2 (angiotensin converting enzyme 2), MAPK8 (mitogen-activated protein kinase 8), TMPRSS2 (transmembrane serine protease 2), IL6 (interleukin 6), TNF (tumor necrosis factor), NFKBIA (NFKB inhibitor alpha)
- **Chemicals:** Silibinin (PubChem CID 31553), Taraxerol (PubChem CID 92097), Beta amyrin (PubChem CID 73145), Cycloartenol (PubChem CID 92110), Alpha-sitosterol (PubChem CID 9548595)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, KCNH2 (potassium voltage-gated channel subfamily H member 2) [NCBI Gene 3757] {aka ERG-1, ERG1, H-ERG, HERG, HERG1, Kv11.1}, PLAG1 (PLAG1 zinc finger) [NCBI Gene 5324] {aka PSA, SGPA, SRS4, ZNF912}, CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ERG (ETS transcription factor ERG) [NCBI Gene 2078] {aka LMPHM14, erg-3, p55}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, TMPRSS2 (transmembrane serine protease 2) [NCBI Gene 7113] {aka PRSS10}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, MPro [NCBI Gene 8673700], ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, N (nucleocapsid phosphoprotein) [NCBI Gene 43740575], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, ORF1ab (ORF1a polyprotein;ORF1ab polyprotein) [NCBI Gene 43740578], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, BAS (Beta-adrenergic stimulation, response to) [NCBI Gene 8213], CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}
- **Diseases:** SASA (MESH:D010534), cancer (MESH:D009369), RMSF (MESH:D011843), inflammation (MESH:D007249), headache (MESH:D006261), FEL (MESH:D051359), flu (MESH:D007251), PDB ID (MESH:C537985), ARDS (MESH:D012128), BC (MESH:D007898), vomiting (MESH:D014839), respiratory failure (MESH:D012131), nausea (MESH:D009325), multi-organ failure (MESH:D009102), infected (MESH:D007239), RCSB PDB (MESH:D011488), chills (MESH:D023341), COVID-19 infections (MESH:D000086382), Toxicity (MESH:D064420), carcinogenicity (MESH:D011230), deaths (MESH:D003643), skin discoloration (MESH:D014075), hematologic abnormalities (MESH:D006402), MM-GBSA (MESH:D041781), infectious diseases (MESH:D003141), nHBD (MESH:D007674)
- **Chemicals:** Nirmatrelvir (MESH:C000718217), 24-Methylenelophenol (MESH:C114722), Remdesivir (MESH:C000606551), rutin (MESH:D012431), thymohydroquinone (MESH:C003465), P (MESH:D010758), tocilizumab (MESH:C502936), Oxygen (MESH:D010100), Taraxerol (MESH:C005802), thymol (MESH:D013943), AMES (MESH:C017501), alkaloids (MESH:D000470), 24-methylene-cycloartenol (MESH:C405143), Erythromycin (MESH:D004917), alpha-hederin (MESH:C000588664), Cao-2 (MESH:C403632), ciclesonide (MESH:C120481), infliximab (MESH:D000069285), niclosamide (MESH:D009534), water (MESH:D014867), octanol (MESH:D000442), ribavirin (MESH:D012254), Cycloartenol (MESH:C100089), Vancomycin (MESH:D014640), alkene (MESH:D000475), essential oil (MESH:D009822), triterpenoids (MESH:D014315), riboflavin (MESH:D012256), Cl- (MESH:D002713), NAG (MESH:D000117), oseltamivir (MESH:D053139), Silibinin (MESH:D000077385), 2-acetamido-2-deoxy-beta-D-glucopyranose (-), carvacrol (MESH:C073316), S (MESH:D013455), potassium (MESH:D011188), Cyclosporine (MESH:D016572), thymoquinone (MESH:C003466), Ritonavir (MESH:D019438), Na+ (MESH:D012964), dithymoquinone (MESH:C113528), Baricitinib (MESH:C000596027), H (MESH:D006859), stigmasterol (MESH:D013265), Chloroquine (MESH:D002738), Folic Acid (MESH:D005492), saponins (MESH:D012503), Molnupiravir (MESH:C000656703), Beta amyrin (MESH:C036380), Th (MESH:D013910), minocycline (MESH:D008911), lipids (MESH:D008055), sterols (MESH:D013261)
- **Species:** Nigella sativa (black-caraway, species) [taxon 555479], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** LOR5 — Mus musculus (Mouse), Transformed cell line (CVCL_5U93), -2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025)

## Figures

23 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978503/full.md

---
Source: https://tomesphere.com/paper/PMC12978503